SCHEMBL1368547

SCHEMBL1368547

COc1cccc(CC(O)C(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.58
CYP1A2 P05177 1/20 0.54
CTBP2 P56545 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM6B O15054 1/20 0.50
HIF1A Q16665 1/20 0.50
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MMP13 P45452 1/20 0.49
LMNA P02545 1/20 0.49
PPARA Q07869 1/20 0.48
MTNR1A P48039 1/20 0.48
MTNR1B P49286 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8953537 1.00 TAAR1 (0.58) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL28019828 1.00 TAAR1 (0.58) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL7511969 1.00 TAAR1 (0.58) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL28020294 0.86 TAAR1 (0.57) TAAR1MEN1KMT2AHIF1AALDH1A1
SCHEMBL4594693 0.86 TAAR1 (0.57) TAAR1MEN1KMT2AHIF1AALDH1A1
SCHEMBL8953540 0.84 PPARA (0.50) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL12191887 0.84 TAAR1 (0.63) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL27836008 0.84 PPARG (0.59) KDM6BPPARA
SCHEMBL12191881 0.84 TAAR1 (0.63) TAAR1CYP1A2CTBP2MEN1KMT2A
SCHEMBL5740450 0.84 TAAR1 (0.63) TAAR1CYP1A2CTBP2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110287059-A1 HONEY ANALYSIS COMVITA NEW ZEALAND LIMITED (NZ) 2011-11-24 US disclosed
EP-2368111-A1 HONEY ANALYSIS Comvita New Zealand Limited (NZ) 2011-09-28 EP disclosed
WO-2010082845-A1 HONEY ANALYSIS COMVITA NEW ZEALAND LIMITED (NZ) 2010-07-22 WO disclosed
EP-0634408-B1 DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF FUJISAWA PHARMACEUTICAL CO (JP) 2002-01-02 EP disclosed
CN-1039331-C Depsispeptide derivative, preparation and application of same FUJISAMA PHARMACEUTICAL CO LTD (JP) 1998-07-29 CN disclosed
EP-0634408-A1 DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-01-18 EP disclosed
CN-1080932-A Depsipeptide derivative and manufacture method thereof and purposes FUJISAWA PHARMACEUTICAL CO (JP) 1994-01-19 CN disclosed
CN-1048852-A The α-Mi Dingyang of new replacement (sulphur) base-and α-triazine oxygen (sulphur) yl carboxylic acid derivative, their preparation method, and they are as weedicide, the application of sterilant and plant-growth regulator SCHERING AG (DE) 1991-01-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110287059-A1 HONEY ANALYSIS GLO1, GLMN, AGER TAAR1 4441/4885CYP1A2 2109/4885CTBP2 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.